| Browse by: | Sort by: |
Using New and Emerging Therapies in Managing of Hypercholesterolemia
Using New and Emerging Therapies in Managing of Hypercholesterolemia
Ira Goldberg, MD
NYU Medical Center, New York, New York
Available
Risk Stratification: Coronary Calcium, ApoB, LDL Particle Size, Lp(a). Which Ones are Worthwhile and Why?
Risk Stratification: Coronary Calcium, ApoB, LDL Particle Size, Lp(a). Which Ones are Worthwhile and Why?
Ira Goldberg, MD
NYU Medical Center, New York, New York
Available
Diabetes and Heart Failure
Diabetes and Heart Failure
Matthew Cavender, MD, MPH
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Available
Q&A/Panel Discussion
Q&A/Panel Discussion
Matthew Cavender, MD, MPH
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Anders Carlson, MD
International Diabetes Center, Minneapolis, Minnesota
Mark Molitch, MD
Northwestern University, Chicago, Illinois
Available
What To Do when Your Patient has a High (or a Low) HDL
What To Do when Your Patient has a High (or a Low) HDL
Jeffrey Barton Boord, MD,MPH
Parkview Health, Fort Wayne, IN
Available
Debate: The LDL Limbo. How Low Should You Go?
Debate: The LDL Limbo. How Low Should You Go?
Alan Chait, MBBS, MD
Univ of WA, Seattle, WA
Steve Nissen, MD
Cleveland Clinic, Cleveland, OH
Henry N Ginsberg, MD
Columbia Univ College of Physicians and Surgeons, New York, NY
Available
Hepatic Substrate Metabolism and Cardiometabolic Disease
Chair
Ira J Goldberg, M.D.
NYU Med Ctr, New York, NY
Available
Hepatic Substrate Metabolism and Cardiometabolic Disease
Shared Mechanisms Linking Sugar-Regulated Carbohydrate and Lipid Metabolism
Mark A Herman, MD
Duke Univ Med Ctr, Durham, NC
Available
Hepatic Substrate Metabolism and Cardiometabolic Disease
Regulation of Lipid and Glucose Metabolism by Bile Acids
Rebecca Haeusler, PhD
Columbia Univ, New York, NY
Available
Hepatic Substrate Metabolism and Cardiometabolic Disease
VLDL Production, Hypertriglyceridemia, and Risk of Vascular Disease
Henry N Ginsberg, MD
Columbia Univ Coll of Phys & S, New York, NY
Available
Recently Arrived and Pipeline Drugs for Dyslipidemia
Recently Arrived and Pipeline Drugs for Dyslipidemia
Anne Carol Goldberg, MD
Washington Univ School of Med, Saint Louis, MO
Available
Designing a Treatment Plan for Patients with T2DM (Including CV Outcomes Considerations)
Designing a Treatment Plan for Patients with T2DM (Including CV Outcomes Considerations)
John (Jack) L Leahy, MD
Univ of VT Coll of Med, Shelburne, VT
Jane E Reusch, MD
Denver VAMC, Denver, CO
Free
Slides + audio
Statin Intolerance
Statin Intolerance
Lisa R Tannock, MD
Univ of Kentucky, Lexington, KY
Available
Cardiovascular Risk Reduction in Diabetes
Cardiovascular Risk Reduction in Diabetes
Peter Gaede, MD, DMSc, Associate Professor
Slagelse Sygehus, Slagelse, Denmark
Available
Primary Aldosteronism: From Physiology to Outcome Data
Evolution Towards Primary Aldosteronism: Part of Adrenal Physiology?
Fabio L Fernandes-Rosa, MD, PhD
INSERM U970, PARCC, Paris, France
Permission not
granted for presentation
granted for presentation
Primary Aldosteronism: From Physiology to Outcome Data
Conn Syndrome: Beyond Secretion of Aldosterone Only
Katharina Lang, MD
Univ of Birmingham, Birmingham, United Kingdom
Available
Primary Aldosteronism: From Physiology to Outcome Data
How Likely Can Primary Aldosteronism Be Cured?
Martin Reincke, MD
Medizinische Klinik und Poliklinik 4, Klinikum der Universität München, Munich, Germany
Available
Sizing Up Extreme Triglyceridemia: How to Spot a Coyote in a Wolf's Clothing
Sizing Up Extreme Triglyceridemia: How to Spot a Coyote in a Wolf's Clothing
Richard L Dunbar, MD
Univ of Pennsylvania, Philadelphia, PA
Available
Management of Diabetes in Patients with ESRD and CKD: Therapeutic Options and Considerations
Management of Diabetes in Patients with ESRD and CKD: Therapeutic Options and Considerations
David Baldwin, Jr., MD
Rush University, Chicago, IL
Available
Debate: What's Next After Metformin in Patients with Type 2 Diabetes and Cardiovascular Disease?
Debate: What's Next After Metformin in Patients with Type 2 Diabetes and Cardiovascular Disease?
Willy M. Valencia, MD, MSc
Miami VA Medical Center, Miami, FL
Available
Debate: What's Next After Metformin in Patients with Type 2 Diabetes and Cardiovascular Disease?
Debate: What's Next After Metformin in Patients with Type 2 Diabetes and Cardiovascular Disease?
Carol H. Wysham, MD
Rockwood Clinic, Spokane, WA
Available
Debate: What's Next After Metformin in Patients with Type 2 Diabetes and Cardiovascular Disease?
Rebuttal: What's Next After Metformin in Patients with Type 2 Diabetes and Cardiovascular Disease?
Willy M. Valencia, MD, MSc
Miami VA Medical Center, Miami, FL
Available
Debate: What's Next After Metformin in Patients with Type 2 Diabetes and Cardiovascular Disease?
Rebuttal: What's Next After Metformin in Patients with Type 2 Diabetes and Cardiovascular Disease?
Carol H. Wysham, MD
Rockwood Clinic, Spokane, WA
Available
Q&A/Panel Discussion with Drs. Carlson, Wysham, and Valencia
Q&A/Panel Discussion with Drs. Carlson, Wysham, and Valencia
Anders L. Carlson, MD
International Diabetes Center, Saint Paul, MN
Carol H. Wysham, MD
Rockwood Clinic, Spokane, WA
Willy M. Valencia, MD, MSc
Miami VA Medical Center, Miami, FL
Available
Challenging Cases from Surgeons and Endocrinologists
A Dilemma of Neuroendocrine Proportion
TK Pandian, MD
Mayo Clinic, Rochester, MN
Free
Slides + audio
